Étude de la cinétique de la bilirubine avant traitement par corticostéroïdes dans l'hépatite alcoolique aigüe sévère
Par : Freyssinet, Marie
Document archivé le : 09/01/2014
Étude de la cinétique de la bilirubine avant traitement par corticostéroïdes dans l'hépatite alcoolique aigüe sévère
Introduction: Acute alcoholic hepatitis (AAH) are treated by corticosteroid
therapy (CT) when the Maddrey DF is = 32. The decrease in total bilirubin at day 7 is a major prognostic factor and a component of the Lille model predicting survival. The aim of our study was to evaluate the impact on survival of the evolution of biological variables as bilirubin in the week before CT initiation. Patients and methods: 106 patients consecutively hospitalized from January 2007 to December 2010 for a severe acute alcoholic hepatitis and having a DF = 32 were included for a retrospective study. Clinical and laboratory data were collected at admission and during hospitalization. All received CT and were alive 7 days after CT initiation; 28 also received N-acetyl cysteine (NAC). Variables affecting survival were analyzed in a Cox model. Results: Mean age was 53 (24-74), 61% were male and 85% had cirrhosis. All patients had an active
consumption of alcohol. The mean time between admission and initiation of CT was
10 days (4-31). The 3 and 6-months survivals were 69 % and 60 %. In multivariate
analysis, younger patients (p=0.04), decrease in bilirubin level at 7 days CT (p
<0.0002), and decrease of bilirubin before steroid (DBBS) (p< 0. 0003) had
better3-months survival. DBBS was observed in 55% of patients and 88% with DBBS
were still alive at 3 months vs 40% without DBBS. This later variable was related to response to CT and adding the DBBS variable to Lille Model or DF increased the AUROC. Conclusion: The present study indicates that in patients with severe acute alcoholic hepatitis, DBBS is a significantly independent predictor for both the response to CT and the 3 months survival. This could help to rapidly define the patients with a poor prognostic for whom other therapies
than CT could be attempted such as transplantation or bio-artificial livers.
13NANT057M
IMPORTANT : OBLIGATIONS DE LA PERSONNE CONSULTANT CE DOCUMENT
Conformément au Code de la propriété intellectuelle, nous rappelons que le document est
destiné à un usage strictement personnel. Les "analyses et les courtes citations justifiées
par le caractère critique, polémique, pédagogique, scientifique ou d'information" sont autorisées
sous réserve de mentionner les noms de l'auteur et de la source (article L. 122-4 du Code de la
propriété intellectuelle). Toute autre représentation ou reproduction intégrale ou partielle,
faite sans le consentement de l'auteur ou de ses ayants droit, est illicite.
De ce fait, nous vous rappelons notamment que, sauf accord explicite de l'auteur de la thèse, vous n'êtes pas autorisé à rediffuser ce document sous quelque forme que ce soit (impression papier, transfert par voie électronique, ou autre). Tout contrevenant s'expose aux peines prévues par la loi.
Fichier(s) associé(s) au document :
freyssinetMED13.pdf
freyssinetMED13.pdf